1319196-77-4

Upstream product

• 916429-26-0 6-bromo-2-chloro-3-iodoquinoline 
• 1057322-63-0 2-chloro-N-(2-hydroxy-1-methyl-ethyl)-acetamide 
• 1810-71-5 6-bromo-2-chloroquinoline 
• 1319196-57-0 6-bromo-3-iodo-N-(4-methoxybenzyl)quinolin-2-amine 
• 119844-67-6 (5R)-5-methylmorpholin-3-one 

Downstream Products

• 1319196-78-5 (R)-6-bromo-N-(4-methoxybenzyl)-3-(3-methylmorpholino)quinolin-2-amine 
• 1319196-79-6 (R)-N-(4-methoxybenzyl)-3-(3-methylmorpholino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinolin-2-amine 
• 1319194-41-6 (R)-(2-(2-amino-3-(3-methylmorpholino)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 

Relevant academic research and scientific papers

AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein ring A, B1, B2, B3, L, R1, R2, ring Z, m and n of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula (I), intermediates and processes useful for the preparation of compounds of Formula (I).